Biology subjects

Ranxhi, B.

Publications and source records attributed to Ranxhi, B..

4 recordsLinked to original sources

bioRxiv2026

Chronic alpha-Synuclein Over-Expression and Ceruloplasmin Challenge Promote Distinct Iron and Redox Responses in M17 Cells

BackgroundWhile -synuclein (-syn) accumulation and iron dysregulation are hallmarks of Parkinsons Disease, the adaptations that enable neuronal survival under chronic protein stress remain unclear. Here, we investigated how -syn overexpression and ceruloplasmin (Cp)-mediated iron modulation alters iron and redox homeostasis. MethodsWe utilized human BE(2)-M17 neuroblastoma cell lines stably expressing different levels of -syn to examine the interplay between -syn, Ceruloplasmin (Cp)-mediated iron modulation, and the cellular response to oxidative stress. Analyses included Western blotting, immunofluorescence staining, soluble/insoluble fractionation, glutathione, reactive oxygen species (ROS) and hydrogen peroxide (H2O2) quantification, lipid peroxidation, ferrous iron, and cell viability. ResultsOur data suggest an unexpected relationship between chronic -syn expression and cellular redox regulation. Despite carrying a greater -syn burden, cells with higher -syn expression exhibit lower basal ROS, H2O2, and lipid peroxidation compared to control cells. These changes are not accompanied by activation of canonical antioxidant pathways suggesting that the reduced oxidative profile arises through alternative mechanisms. Besides, -syn over-expressing cells display significant remodeling of iron-handling pathways, including altered expression of ferritin heavy chain, transferrin receptor, and ferroportin, suggesting that chronically high -syn levels are associated with changes in iron homeostasis. In addition, this phenotype is not maintained following Cp overexpression. Although Cp reduces Fe{superscript 2} levels, it also induces substantial increases in ROS and H2O2 without corresponding changes in GPX4, glutathione, or related antioxidant systems. Thus, the reduced basal oxidative profile observed in -syn-over-expressing cells does not reflect enhanced canonical antioxidant capacity. Instead, chronically high -syn levels appear to be associated with adaptive remodeling of iron and redox pathways that become sensitive to oxidative imbalance. ConclusionChronic -syn over-expression promotes adaptive remodeling of iron and redox homeostasis, associated with reduced basal oxidative stress but increased sensitivity to Cp-mediated perturbation. These data link -syn burden to iron metabolism and stress-dependent vulnerability in synucleinopathies. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=140 SRC="FIGDIR/small/732494v1_ufig1.gif" ALT="Figure 1"> View larger version (50K): org.highwire.dtl.DTLVardef@9ab785org.highwire.dtl.DTLVardef@186a200org.highwire.dtl.DTLVardef@1f5c13forg.highwire.dtl.DTLVardef@162249e_HPS_FORMAT_FIGEXP M_FIG C_FIG

neuroscience↗

bioRxiv2025

Regulation of polyamine interconversion enzymes affects α-Synuclein levels and toxicity in a Drosophila model of Parkinsons disease

Parkinson's Disease (PD) is a prevalent neurodegenerative disorder with the accumulation and aggregation of alpha-synuclein (&[alpha]-Syn) as a central pathological hallmark. Misfolding and aggregation of &[alpha]-Syn disrupts cellular homeostasis, hinders mitochondrial function, and activates neuroinflammatory responses, ultimately resulting in neuronal death. Recent biomarker research indicated a notable increase in the serum concentrations of three L-ornithine-derived polyamines (PAs): putrescine, spermidine, and spermine, each correlating with the progression of PD and its clinical subtypes. However, the role of PA pathways in PD pathology is poorly understood; it is unclear whether elevated PA concentrations are linked to PD pathology or whether they represent a secondary effect. In this study, we targeted PAs through RNAi knockdown of different PA-interconversion enzymes (PAIE) in a Drosophila melanogaster model of PD that overexpresses human, wild-type &[alpha]-Syn. Our findings reveal a significant impact on both the lifespan and motility of PD-model flies when crucial PAIE, such as ornithine decarboxylase 1 (ODC1), spermidine synthase (SRM), spermidine/spermine N1-acetyltransferase 1 (SAT1), and spermine oxidase (SMOX), are targeted. The overexpression of SAT1 and SMOX in this PD model had positive, enduring effects on fly lifespan. Additionally, we noted significant alterations in &[alpha]-Syn protein levels when PAIE are either knocked down or overexpressed. These findings underscore the role of PA pathways in PD and their potential targeting to modulate &[alpha]-Syn levels and mitigate neurodegeneration in PD.

neuroscience↗

bioRxiv2023

Progressive degeneration in a new Drosophila model of Spinocerebellar Ataxia type 7

Spinocerebellar ataxia type 7 (SCA7) is a progressive neurodegenerative disorder resulting from abnormal expansion of polyglutamine (polyQ) in its disease protein, ataxin-7 (ATXN7). ATXN7 is part of Spt-Ada-Gcn5 acetyltransferase (SAGA), an evolutionarily conserved transcriptional coactivation complex with critical roles in chromatin remodeling, cell signaling, neurodifferentiation, mitochondrial health and autophagy. SCA7 is dominantly inherited and characterized by genetic anticipation and high repeat-length instability. Patients with SCA7 experience progressive ataxia, atrophy, spasticity, and blindness. There is currently no cure for SCA7, and therapies are aimed at alleviating symptoms to increase quality of life. Here, we report novel Drosophila lines of SCA7 with polyQ repeats in wild-type and human disease patient range. We find that ATXN7 expression has age- and polyQ repeat length-dependent reduction in survival and retinal instability, concomitant with increased ATXN7 protein aggregation. These new lines will provide important insight on disease progression that can be used in the future to identify therapeutic targets for SCA7 patients.

neuroscience↗

bioRxiv2019

Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia Type 3 disease protein

BackgroundSpinocerebellar Ataxia type 3 (SCA3, also known as Machado-Joseph disease) is a neurodegenerative disorder caused by a CAG repeat expansion encoding an abnormally long polyglutamine (polyQ) tract in the disease protein, ataxin-3 (ATXN3). No preventive treatment is yet available for SCA3. Because SCA3 is likely caused by a toxic gain of ATXN3 function, a rational therapeutic strategy is to reduce mutant ATXN3 levels by targeting pathways that control its production or stability. Here, we sought to identify genes that modulate ATXN3 levels as potential therapeutic targets in this fatal disorder.\n\nMethodsWe screened a collection of siRNAs targeting 2742 druggable human genes using a cell-based assay based on luminescence readout of polyQ-expanded ATXN3. From 317 candidate genes identified in the primary screen, 100 genes were selected for validation. Among the 33 genes confirmed in secondary assays, 15 were validated in an independent cell model as modulators of pathogenic ATXN3 protein levels. Ten of these genes were then assessed in a Drosophila model of SCA3, and one was confirmed as a key modulator of physiological ATXN3 abundance in SCA3 neuronal progenitor cells.\n\nResultsAmong the 15 genes shown to modulate ATXN3 in mammalian cells, orthologs of CHD4, FBXL3, HR and MC3R regulate mutant ATXN3-mediated toxicity in fly eyes. Further mechanistic studies of one of these genes, FBXL3, encoding a F-box protein that is a component of the SKP1-Cullin-F-box (SCF) ubiquitin ligase complex, showed that it reduces levels of normal and pathogenic ATXN3 in SCA3 neuronal progenitor cells, primarily via a SCF complex-dependent manner. Bioinformatic analysis of the 15 genes revealed a potential molecular network with connections to tumor necrosis factor-/nuclear factor-kappa B (TNF/NF-kB) and extracellular signal-regulated kinases 1 and 2 (ERK1/2) pathways.\n\nConclusionsWe identified 15 druggable genes with diverse functions to be suppressors or enhancers of pathogenic ATXN3 abundance. Among identified pathways highlighted by this screen, the FBXL3/SCF axis represents a novel molecular pathway that regulates physiological levels of ATXN3 protein.

neuroscience↗